Canadian biotech VC Amplitude raises $192M second fund

Amplitude Ventures, a Montreal-based life sciences VC firm, has raised a second fund to deploy into 14 to 16 startups.

Dion Madsen

The $263 million CAD ($192 million) precision medicine fund has already invested in inflammatory diseases biotech Evommune, AbbVie- and Gilead-partnered company Tentarix Biotherapeutics and two Vancouver startups: Reverb Therapeutics and Evolved Therapeutics. A fifth investment will close this week, Amplitude partner Dion Madsen told Endpoints News.

It follows the firm’s first fund, which had a final close of approximately $200 million CAD ($145 million) in June 2021. The inaugural fund has supported companies like radiotherapeutics startup Abdera, drug discovery shop Congruence, Radiant Biotherapeutics, Repare Therapeutics and AI startup Valence, which Recursion bought last…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks